Medcura Technologies IP Asset Sale

Medcura logo4doctor-medical-medicine-health-42273

Paul Cooper and David Rubin of David Rubin & Partners Limited, the Joint Administrators of Medcura Technologies Limited (in Administration) (“Medcura” or the “Company”), have appointed Metis Partners to support the marketing and sale of the intellectual property (“IP”) assets relating to the Company.

IP ASSET HIGHLIGHTS

  • Attractive Proven Medical Technology
  • Proprietary Software and Source Code
  • Well-regarded Brand and Reputation
  • UK Trade Mark Protection
  • Branded Website

This is a unique opportunity to acquire the IP assets of Medcura, an industry leader in the healthcare technology market, specialising in intravenous (“IV”) preparation in hospital pharmacies.

SALE

All offers and requests for more information should be submitted by email directly to Morven Fraser at morven@metispartners.com. The deadline for offers has been set at Wednesday 7th June, 2017 at noon.

TECHNOLOGY OVERVIEW

Medcura was an industry healthcare technology company, founded to bring cloud-based, compound management software (“CMS”) for IV preparation to hospitals and compounding pharmacies.

The CMS has undergone the required risk analysis and validation processes, and it is fully compliant with Good Manufacturing Practice (“GMP”) standards and the regulations necessary for obtaining and maintaining a Medicines and Healthcare products Regulatory Agency (“MHRA”) licence.

The Company’s technology is designed to help manage the IV drug delivery process from order receipt, through management of raw materials and production processes, to product release and patient administration of the final product. By electronically controlling the processes around producing patient-specific doses, the technology mitigates the risk of errors associated with manual practices and increases cost efficiency through minimising drug wastage. The CMS tracks every user transaction and provides detailed batch record documentation, facilitating efficient investigation of any incident and enhancing GMP and MHRA compliance.

The Medcura technology is designed to cater for a wide range of IV aseptic products and services including: chemotherapy, clinical trials, products with single/multiple drugs, for patient specific or batch production. The CMS is also flexible and supports a number of final containers including syringes, infusion bags, elastomeric devices, drops and oral solutions.

The CMS helps increase efficiency and mitigate risks associated with human error in the compounding process and can significantly reduce associated costs. The Company has spent around £670k on developing and advancing its technology, and is now managing all of the University Hospital Southampton’s 120 oncology compounded finished products. To date, the hospital has been able to make savings of circa £300k – £400k.

Medcura could provide further opportunities for companies operating in the medical technology, pharmaceutical and software development markets.

IP ASSETS FOR SALE

  • Proprietary Software and Source Code
  • Registered UK Trade Mark
  • Goodwill in the Brand and Reputation
  • Branded Domain Name and Website Content
SHARE THIS PAGE VIA: Share on LinkedInTweet about this on TwitterShare on FacebookShare on Google+Pin on PinterestEmail this to someoneDigg thisBuffer this pageShare on RedditShare on Tumblr